1. Home
  2. Knowledge Base
  3. References
  4. Reduction of falls in a rat model of PD falls by the M1 PAM TAK-071

Reduction of falls in a rat model of PD falls by the M1 PAM TAK-071

Kucinski A, Sarter M (2021) Reduction of falls in a rat model of PD falls by the M1 PAM TAK-071. Psychopharmacology (Berl) 238(7):1953-1964. doi: 10.1007/s00213-021-05822-x

Summary: In addition to the disease-defining motor symptoms, patients with Parkinson’s disease (PD) exhibit gait dysfunction, postural instability, and a propensity for falls. The muscarinic M1-positive allosteric modulator (PAM) TAK-071 improves the attentional performance of rats with BF cholinergic losses. The authors previously developed a rodent model of PD falls by demonstrating that rats with dual basal forebrain cholinergic and mediodorsal striatal dopamine losses (“DL rats”) exhibit a heightened fall rate when required to traverse dynamic surfaces. This study tested the hypothesis that TAK-071 reduces fall rates in DL rats.

Usage: Rats received bilateral infusions of 192-IgG-SAP (200 ng/μL; 0.8 μL/hemisphere) or an equal volume of artificial cerebral spinal fluid into the nucleus basalis and substantia innominata of the basal forebrain.

Related Products: 192-IgG-SAP (Cat. #IT-01)